# Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM

Study · id `cardio:ct-nct06762223` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06762223](<https://clinicaltrials.gov/study/NCT06762223>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06762223

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 190 participants.

## Technical summary

Registry record NCT06762223. Randomized; triple masking; primary purpose treatment. Start 2024-12-31 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 190 participants (planned count; ClinicalTrials.gov record NCT06762223, source copy `cardio:ctgov-nct06762223-2025-01-07`, retrieved 2026-10-26)
- Planned start: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT06762223, source copy `cardio:ctgov-nct06762223-2025-01-07`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06762223, source copy `cardio:ctgov-nct06762223-2025-01-07`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06762223, source copy `cardio:ctgov-nct06762223-2025-01-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06762223, source copy `cardio:ctgov-nct06762223-2025-01-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06762223-2025-01-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
- Condition: Metabolic Dysfunction-associated Steatotic Liver Disease
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Henagliflozin 10 mg daily
- Intervention (Drug): Metformin 1700 mg daily
- Intervention (Other): Placebo of Henagliflozin
- Lead sponsor: Xiqiao Zhou
- Lead sponsor class: OTHER
- Collaborator: Jiangsu Hengrui Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 4146b0514aec4c569d6fb81d193a173821b89fc4fb1be838c16ea75df26367a7
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
